Recruiting
Phase 2

Risk-adapted Therapy

Sponsor:

Jonathan Schoenfeld, MD, MPH

Code:

NCT04900623

Conditions

HPV-Associated Oropharyngeal Squamous Cell Carcinoma

HPV Positive Oropharyngeal Squamous Cell Carcinoma

HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage

HPV-Related Squamous Cell Carcinoma

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Interventions

NavDx HPV ctDNA Testing

Radiotherapy

Chemotherapy drug

Study Details

Brief summary:

This research is being conducted to understand if treatment can be tailored for participants with HPV-related oropharynx cancers using both clinical features (stage of the tumor, smoking status) combined with an investigational HPV blood test.

The names of the test and treatments involved in this study are:

  • NavDx® HPV ctDNA testing (HPV blood test)
  • Radiation therapy
  • Chemotherapy: Cisplatin, or Carboplatin and Paclitaxel (not all participants receive any or all of these agents)

Conditions

HPV-Associated Oropharyngeal Squamous Cell Carcinoma

HPV Positive Oropharyngeal Squamous Cell Carcinoma

HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage

HPV-Related Squamous Cell Carcinoma

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Study ID

NCT04900623

Start date

Jul 2, 2021

Status verified date

Aug, 2026

Completion date

Jun 1, 2032

Anticipated

Primary completion date

Jun 1, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must meet the following eligibility criteria at the time of screening to be eligible to participate in the study:
  • Subject must have histologically or cytologically confirmed, stage I, II, or III (N3 disease excluded), HPV associated oropharyngeal (tongue base or tonsil) squamous cell carcinoma, as defined by 2017 American Joint Committee on Cancer (AJCC), 8th edition staging.

\-- Patients with HPV-associated disease of unknown primary (cT0) are eligible
  • HPV status should be confirmed on tissue biopsy or cytologic sample by any of the following:

  • Immunohistochemical staining for p16 with ≥70% expression
  • Confirmatory DNA testing (PCR or ISH) for high-risk subtype
  • Willing to provide blood and tissue from a diagnostic biopsy and blood samples before, during, and after treatment.
  • Detectable HPV ctDNA blood sample at baseline, prior to treatment, using the NavDx® assay that detects HPV subtype 16
  • Age 22 years or older
  • ECOG performance status ≤ 2
  • Participants should have adequate organ and marrow function if they are to receive chemotherapy (cisplatin, or carboplatin and paclitaxel) with radiation concurrently as determined by standard institutional guidelines and investigator preference (parameters suggested below).

  • absolute neutrophil count (ANC) ≥ 1000
  • platelet count ≥ 100,000
  • total bilirubin of 1.5 or less
  • creatinine of 1.6 or less (or a CrCl ≥50 mL/min) per institutional standards.
  • Planning to receive non-surgical management for HPV+ oropharyngeal cancer
  • Ability to understand and the willingness to sign a written informed consent document.
  • Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of (chemo)radiation therapy. "Women of childbearing potential (WOCBP)" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level above 40 mIU/mL.
  • Men who are sexually active with WOCBP must agree to use any contraceptive method with a failure rate of less than 1% per year. Men who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 1 month after treatment. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception.

Exclusion Criteria:

  • Patients with AJCC 2017 8th edition stage IVC (metastatic) disease; or patients with fixed cervical nodal disease suggesting extranodal extension or N3 disease as suggested by lymph nodes measuring >6 cm.
  • Subject who has had prior radiation and/or chemotherapy for head and neck cancer.
  • Any history of oncologic surgical resection (transoral robotic surgery, TORS) or oncologic neck dissection prior to undergoing definitive RT or chemoradiation. Note: prior tonsillectomy as part of identification of the primary tumor site or biopsy and excisional nodal biopsy is/are acceptable provided the patient would be standardly treated to definitive treatment doses of therapy off protocol. Patients with HPV-associated unknown primary should not have undergone a neck dissection to be eligible.
  • Undetectable baseline HPV ctDNA result by NavDx® testing or detectable baseline HPV ctDNA result for subtypes 18, 31, 33, or 35.
  • Pregnant or lactating women.
  • Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, and low risk prostate adenocarcinoma being managed with active surveillance. A history of another separate malignancy in remission without evidence of active disease is permitted if chance3 of recurrence is thought to be low.

Study Design

Enrollment

145 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: LOW RISK RT (ALONE OR WITH SOC CHEMO

The research study procedures include: screening for eligibility, and study treatments including evaluations and follow-up visits

  • NavDx HPV ctDNA Testing: Blood will be collected and shared with an outside lab for analysis (less than 10 mL of blood or about 2 teaspoons). The results of this test will determine what radiation dose received . The specimens will be de-identified. The specimens will be banked for future use.
  • Radiation Therapy: Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.
  • Chemotherapy: Chemotherapy and radiation therapy are both considered standard treatments for your type of cancer. The study doctor will decide whether or not chemotherapy with radiation and the type of chemotherapy.

  • Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.
  • Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy

experimental: INTERMEDIATE RISK RT (ALONE OR WITH SOC CHEMO

The research study procedures include: screening for eligibility, and study treatments including evaluations and follow-up visits

  • NavDx HPV ctDNA Testing: Blood will be collected and shared with an outside lab for analysis (less than 10 mL of blood or about 2 teaspoons). The results of this test will determine what dose of radiation received. The specimens will be de-identified. The specimens will be banked for future use.
  • Radiation Therapy: Higher risk participants will receive standard radiation dose for up to 7-8 weeks
  • Chemotherapy: Chemotherapy and radiation therapy are both considered standard treatments for your type of cancer. The study doctor will decide whether or not chemotherapy with radiation and the type of chemotherapy.

  • Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.
  • Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy

Interventions

NavDx HPV ctDNA Testing

Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.

Radiotherapy

Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.

Chemotherapy drug

Chemotherapy and radiation therapy are both considered standard treatments

  • Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.
  • Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy.

Primary outcome measure

  • Progression Free Survival 2 Years [ Time Frame: 2 Years ]

Central Contacts and Locations

Central contacts

Jonathan Schoenfeld, MD, MPH

617-632-3591jonathan_schoenfeld@dfci.harvard.edu

Locations

Brigham and Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Jonathan Schoenfeld, MD, MPH

617.632.5296jonathan_schoenfeld@dfci.harvard.edu

Principal Investigator:

Jonathan Schoenfeld, MD, MPH

Dana Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Jonathan D. Schoenfeld, MD, MPH

617.632.5296jonathan_schoenfeld@dfci.harvard.edu

Principal Investigator:

Jonathan D. schoenfeld, MD

More Information

Sponsor

Jonathan Schoenfeld, MD, MPH

Last update posted

Aug 5, 2026

Last verified

Aug, 2026

Keywords

  • HPV-Associated Oropharyngeal Squamous Cell Carcinoma
  • HPV Positive Oropharyngeal Squamous Cell Carcinoma
  • HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage
  • HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage
  • Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Jonathan Schoenfeld, MD, MPH on 2026-08-05.